Hem › Bröstcancer › Oregon › Portland

Kliniska studier för Bröstcancer i Portland, OR

33 studier för Bröstcancer söker deltagare vid platser i och runt Portland (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.

Officiell studietext (engelska)

Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

RekryterarFas 3

Oregon Health & Science University, Knight Cancer Institute, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 5 okt. 2026 · NCT06982521

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

RekryterarFas 1/2

Oregon Health & Science University (OHSU), Portland

Ålder 12 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT04585750

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

RekryterarFas 3

Northwest Cancer Specialists, Portland

Ålder 18 till 100 · Alla kön · Uppdaterad 2 okt. 2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekryterarObservationsstudieFriska volontärer välkomna

Providence Portland Medical Center, Portland
Providence Saint Vincent Medical Center, Portland
Providence Willamette Falls Medical Center, Oregon City · 12 mi bort

Ålder 40 till 75 · Alla kön · Uppdaterad 2 okt. 2026 · NCT05334069

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

RekryterarFas 1/2

Compass Oncology - Rose Quarter Cancer Center, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT07701941

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

RekryterarFas 1

Research Site, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT05877599

Study of AVZO-021 in Patients With Advanced Solid Tumors

RekryterarFas 1/2

Avenzo Therapeutics Recruiting Site, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT05867251

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

RekryterarFas 3

Providence Portland Medical Center ( Site 0044), Portland
Providence St. Vincent Medical Center ( Site 0081), Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06312176

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

RekryterarFas 2

Oregon Health and Science University, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07007559

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

RekryterarFas 1/2

Providence Portland Medical Center, Portland
Providence St. Vincent Medical Center, Portland
Local Institution - 0052, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT06618287

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

RekryterarFas 3

Clinical Trial Site, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT07085767

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

RekryterarFas 3

Oregon Health and Science University, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

RekryterarFas 2

Providence Portland Medical Center, Portland
Providence St. Vincent Medical Center, Portland

Ålder 18 och äldre · Kvinnor · Uppdaterad 22 sep. 2026 · NCT07287098

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

RekryterarFas 3

Providence Portland Medical Center, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT07173751

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

RekryterarFas 3

Providence Cancer Institute Franz Clinic, Portland
Providence Cancer Institute Franz Clinic, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 15 sep. 2026 · NCT06492616

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

RekryterarFas 1

Providence Portland Medical Center, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 10 sep. 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

RekryterarFas 1

Providence Cancer Institute, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT06253871

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

RekryterarFas 3

Providence Portland Medical Center, Portland
Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland

Ålder 18 och äldre · Alla kön · Uppdaterad 3 sep. 2026 · NCT06790693